## Prostate Adenocarcinoma — Pathology & Clinical Management ### Epidemiology & Risk Factors **Key Point:** Prostate adenocarcinoma is the most common malignancy in men in developed nations. Risk factors include age >65 years, family history, African ancestry, and possibly dietary factors (high fat, low lycopene). ### Anatomical Origin & Histopathology **High-Yield:** The **peripheral zone** is the site of origin in ~70% of adenocarcinomas. This is clinically significant because peripheral zone tumors are more likely to be detected by DRE and biopsy compared to transition zone BPH. | Feature | Adenocarcinoma | BPH | |---------|---|---| | **Zone of origin** | Peripheral zone (~70%) | Transition zone | | **Basal cell layer** | Absent/disrupted | Intact, preserved | | **p63/34βE12 staining** | Negative (loss of basal cells) | Positive (intact basal layer) | | **Glandular pattern** | Infiltrative, disorganized | Organized nodules | **Clinical Pearl:** Immunohistochemical markers (p63, 34βE12, CK5/6) are crucial for distinguishing adenocarcinoma (basal cell loss) from benign mimics (basal cell preserved). This distinction is especially important in small biopsies or atypical glandular proliferations. ### Gleason Grading System **Mnemonic: GLEASON = Glandular Lesion Evaluation And Scoring On Neoplasia** 1. **Basis**: Based on glandular differentiation patterns (architectural, not cytological) 2. **Scoring**: Primary pattern (most common) + secondary pattern (second most common) = Gleason score 3. **Range**: 2–10 (though scores <6 are rarely reported in modern practice) 4. **Prognostic significance**: Gleason score is the **single most important prognostic factor** after stage - Score 6: Well-differentiated, low risk - Score 7: Intermediate risk (3+4 better than 4+3) - Score 8–10: Poorly differentiated, high risk **Warning:** Gleason score is NOT based on cytological atypia or mitotic rate — it is purely architectural. A Gleason 7 (3+4) tumor in this case indicates intermediate-risk disease with predominantly well-differentiated glands and a minority of moderately differentiated component. ### PSA Screening Controversy **High-Yield:** The statement that "early detection by PSA screening in all asymptomatic men >40 years is the gold standard for reducing prostate cancer mortality" is **NOT supported by current guidelines**. #### Current Screening Recommendations (as of 2023) | Organization | Recommendation | |---|---| | **USPSTF (2018)** | Shared decision-making for men 55–69 years; screening NOT recommended >70 years | | **ACS** | Shared decision-making for men >50 years (or >40 if high-risk: African American, family history) | | **AUA** | Shared decision-making for men 45–69 years; baseline PSA may guide future screening intervals | | **NCCN** | Risk-stratified approach; NOT universal screening in all men >40 years | **Clinical Pearl:** PSA screening has **NOT been proven to reduce overall mortality** in large randomized trials (PLCO, ERSPC). While it may detect more cancers, it also leads to overdiagnosis of indolent tumors and unnecessary biopsies, causing morbidity (infection, bleeding, erectile dysfunction, anxiety). **Warning:** Universal PSA screening in asymptomatic men is NOT the standard of care. Current practice emphasizes **shared decision-making** after discussion of benefits (early detection) and harms (overdiagnosis, overtreatment). ### Why the Incorrect Option is Wrong Option 4 falsely claims that "early detection by PSA screening in all asymptomatic men >40 years is recommended as the gold standard." This is **incorrect** because: - Universal screening in all men >40 is NOT recommended by major guidelines (USPSTF, ACS, AUA). - PSA screening has NOT been shown to reduce overall mortality in randomized trials. - Current practice emphasizes **shared decision-making** and risk stratification, not universal screening. - Overdiagnosis and overtreatment of indolent cancers are significant harms of universal screening. [cite:Robbins 10e Ch 20; Harrison 21e Ch 95]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.